The novel Interleukin-1 cytokine family members in inflammatory diseases

Current Opinion in Rheumatology

Volumn 29, Issue 2, 2017, Pages 208-213

  Hahn, Madelaine ^a   Frey, Silke ^a   Hueber, Axel J ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Inflammatory arthritis; Inflammatory bowel disease; Interleukin 1 family; Neutrophil granulocytes; Psoriasis

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 36; INTERLEUKIN 36 RECEPTOR ALPHA; INTERLEUKIN 36ALPHA; INTERLEUKIN 36BETA; INTERLEUKIN 36GAMMA; INTERLEUKIN 37; INTERLEUKIN 38; UNCLASSIFIED DRUG; IL-38 PROTEIN, HUMAN; IL37 PROTEIN, HUMAN; INTERLEUKIN 36, HUMAN; INTERLEUKIN DERIVATIVE;

AUTOIMMUNITY; CROHN DISEASE; EPITHELIUM CELL; EX VIVO STUDY; GOUT; IMMUNOPATHOGENESIS; IN VITRO STUDY; INFLAMMATORY DISEASE; MOLECULAR INTERACTION; MONONUCLEAR CELL; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RECEPTOR UPREGULATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLAMMATION; MOUSE; RHEUMATIC DISEASE;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; GOUT; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; PSORIASIS; RHEUMATIC DISEASES;

EID: 85002410806     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000361     Document Type: Review

References (45)

1. Sims JE, Nicklin MJ, Bazan J.F., et al. A new nomenclature for IL-1-family genes. Trends Immunol 2001; 22:536-537.
2. Dinarello C, Arend W, Sims J., et al. IL-1 family nomenclature. Nat Immunol 2010; 11:973.
3. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226:10-18.
4. Sims JE, Smith DE The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10:89-102.
5. Towne JE, Garka KE, Renshaw B.R., et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004; 279:13677-13688.
6. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 2002; 99:13723-13728.
7. Vigne S, Palmer G, Martin P., et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012; 120:3478-3487.
8. Gabay C, Towne JE Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 2015; 97:645-652.
9. van de Veerdonk FL, Stoeckman AK, Wu G, et al IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012; 109:3001-3005.
10. Blumberg H, Dinh H, Trueblood E.S., et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 2007; 204:2603-2614.
11. Tauber M, Bal E, Pei X.Y., et al. IL36RN mutations impact on protein expression and function: a basis for genotype-phenotype correlation in pustular diseases. J Invest Dermatol 2016; 136:1811-1819.
12. Song HS, Kim SJ, Park T.I., et al. Immunohistochemical comparison of IL-36 and the IL-23/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Ann Dermatol 2016; 28:451-456.
13. Robinson MS. Adaptable adaptors for coated vesicles. Trends Cell Biol 2004; 14:167-174.
14. Mahil SK, Twelves S, Farkas K., et al. AP1S3 mutations cause skin autoin-flammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol 2016; 136:2251-2259.
15. Marrakchi S, Guigue P, Renshaw B.R., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620-628.
16. Hueber AJ, McInnes IB Immune regulation in psoriasis and psoriatic arthritis - recent developments. Immunol Lett 2007; 114:59-65.
17. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361.
18. Frey S, Derer A, Messbacher M.E., et al. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2013; 72:1569-1574.
19. Boutet MA, Bart G, Penhoat M., et al. Distinct expression of interleukin (IL) - 36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol 2016; 184:159-173.
20. Derer A, Groetsch B, Harre U., et al. Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLoS One 2014; 9:e101954.
21. Lamacchia C, Palmer G, Rodriguez E., et al. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther 2013; 15:R38.
22. Kaser A, Zeissig S, Blumberg RS Inflammatory bowel disease. Annu Rev Immunol 2010; 28:573-621.
23. Scheibe K, Backert I, Wirtz S., et al. IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut 2016; doi:10.1136/gutjnl-2015-310374.
24. Nishida A, Hidaka K, Kanda T., et al. Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 2016; 22:303-314.
25. Mok CC, Lau CS Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481-490.
26. Ichii O, Otsuka S, Sasaki N., et al. Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. Lab Invest 2010; 90:459-475.
27. Chu M, Wong CK, Cai Z, et al Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus. Molecules 2015; 20:19588-19604.
28. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000; 9:1-10.
29. Towne JE, Renshaw BR, Douangpanya J, et al Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011; 286:42594-42602.
30. Henry CM, Sullivan GP, Clancy D.M., et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep 2016; 14:708-722.
31. Macleod T, Doble R, McGonagle D., et al. Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist. Sci Rep 2016; 6:24880.
32. Kumar S, Hanning CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002; 18:61-71.
33. Novick D, Kim SH, Fantuzzi G, et al Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10:127-136.
34. Martinon F, Glimcher LH Gout: new insights into an old disease. J Clin Invest 2006; 116:2073-2075.
35. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther 2006; 8 (Suppl 1):S3.
36. Zeng M, Dang W, Chen B., et al. IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response. Clin Rheumatol 2016; 35:2251-2258.
37. Yang L, Zhang J, Tao J., Lu T. Elevated serum levels of interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. APMIS 2015; 123:1025-1031.
38. Ye L, Jiang B, Deng J., et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol 2015; 194:5110-5119.
39. Cavalli G, Koenders M, Kalabokis V., et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford) 2016. [Epub ahead of print].
40. Saeed J, Kitaura H, Kimura K., et al. IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo. Immunol Lett 2016; 175: 8-15.
41. Wu GC, Li HM, Wang J.B., et al. Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus 2016; 25:1377-1380.
42. Bensen JT, Dawson PA, Mychaleckyj J.C., Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res 2001; 21:899-904.
43. Lin H, Ho AS, Haley-Vicente D, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001; 276:20597-20602.
44. Rudloff I, Godsell J, Nold-Petry CA, et al. Brief report: Interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67:3219-3225.
45. Mora J, Schlemmer A, Wittig I., et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol 2016. [Epub ahead of print].